Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Am J Health Syst Pharm ; 67(7): 535-41, 2010 Apr 01.
Artigo em Inglês | MEDLINE | ID: mdl-20237381

RESUMO

PURPOSE: The effect of i.v. chromium administration on glucose control in two patients receiving enteral nutrition is described. SUMMARY: Chromium supplementation has been hypothesized to potentiate the actions of insulin in facilitating cellular uptake of glucose. We report two cases-one involving a diabetic patient and the other a nondiabetic patient-in which chromium administration appeared to decrease insulin requirements. In case 1, a diabetic patient given a single course of chromic chloride appeared to have a probable response to the drug. Within the first day of chromic chloride administration, insulin requirements declined. When chromic chloride was discontinued, insulin requirements did not rise, suggesting efficacy and sustained effect. The patient's glucose intake and blood glucose levels remained relatively stable, while there was a significant decline in insulin requirements. Serum chromium levels were not assessed, so it is uncertain if the patient experienced chromium deficiency or if it was adequately treated with chromium supplementation, and a dose-response relationship could not be ascertained because the patient received a continuous infusion of chromium. In case 2, the insulin requirements of a nondiabetic patient appeared to decrease in response to multiple courses of chromic chloride. Upon initial discontinuation of chromic chloride, the patient's lower insulin requirements were sustained for a few days, but changes in clinical status and other medications precipitated elevated insulin requirements and the need for subsequent chromic chloride administration. Further research in more controlled settings is necessary to elucidate chromium's effect on insulin requirements. CONCLUSION: Infusion of chromic chloride appeared to reduce insulin requirements in one diabetic patient and one nondiabetic patient.


Assuntos
Glicemia/metabolismo , Cloretos/uso terapêutico , Compostos de Cromo/uso terapêutico , Diabetes Mellitus/sangue , Diabetes Mellitus/tratamento farmacológico , Nutrição Enteral , Acidentes de Trânsito , Delirium por Abstinência Alcoólica/tratamento farmacológico , Delirium por Abstinência Alcoólica/psicologia , Intoxicação Alcoólica , Cloretos/administração & dosagem , Compostos de Cromo/administração & dosagem , Diabetes Mellitus Tipo 2/sangue , Diabetes Mellitus Tipo 2/complicações , Diabetes Mellitus Tipo 2/tratamento farmacológico , Humanos , Hipoglicemiantes/administração & dosagem , Hipoglicemiantes/uso terapêutico , Injeções Intravenosas , Insulina/administração & dosagem , Insulina/uso terapêutico , Resistência à Insulina , Masculino , Metilprednisolona/uso terapêutico , Pessoa de Meia-Idade , Pancreatite/complicações , Pancreatite/tratamento farmacológico , Infecções por Pseudomonas/complicações , Infecções por Pseudomonas/tratamento farmacológico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...